|
|
||||||||
Eur J Cardiothorac Surg 2003;23:209-213
© 2003 Elsevier Science NL
Department of Thoracic Surgery, Jiangsu Institute of Cancer Research, Baziting 42#, Nanjing 210009, People's Republic of China
Received 20 August 2002; received in revised form 1 November 2002; accepted 4 November 2002.
* Corresponding author. Tel.: +86-025-3353520
e-mail: fcw{at}public1.ptt.js.cn
| Abstract |
|---|
|
|
|---|
Key Words: Lung neoplasms Surgery Prognosis Bronchoplasty Pulmonary artery reconstruction
| 1. Introduction |
|---|
|
|
|---|
| 2. Materials and methods |
|---|
|
|
|---|
2.1. Surgical indications
Bronchoplasty is the procedure of choice for anatomically suitable central lung cancer or when reduced pulmonary reserve precludes extensive resection, for which the alternative is a pneumonectomy. When tumor surrounding the upper lobe or main bronchus and involving PA to a variable extent or full circumference, bronchovascular reconstruction is indicated. If the radical resection cannot be performed or the two ends of PA cannot be brought together, pneumonectomy is performed. If the patients with inadequate pulmonary or/and cardiac function cannot tolerate a pneumonectomy, palliative bronchoplasty is done.
Chest films and computerized tomographic (CT) examination combined with precise bronchoscopic assessment define the need and probability for bronchoplasty and PA reconstruction. Bronchoscopy is done by thoracic surgeons. When tumor from a lobe orifice is found, cartilage rings of main-stem bronchus are counted to delineate the extent of tumor and plan the resection lines. In this series, 61 patients (78.2%) had an obvious tumor bulge from a lobe orifice, 11 patients (14.1%) had narrow change in bronchial lumen, and six patients (7.7%) were normal under bronchoscopy. Twenty-six patients (34.7%) had inadequate pulmonary (n=21) and cardiac (n=5) function to tolerate pneumonectomy.
2.2. Operative technique
The procedure for bronchoplasty was identical to that for standard lobectomy until the bronchus was isolated. Care was taken not to devascularize the bronchus beyond the proposed line. Frozen section examinations were routinely done by sending a thin ring of tissue from the margins to be anastomosed. The bronchial anastomoses were performed with interrupted absorbable 3-0 sutures applied transmurally, knots being tied outside the bronchial lumen. Any luminal disparity was equalized by stretching the smaller lumen to the size of the larger one. When the operation associated with a double reconstruction of the bronchus and PA, PA was performed with clamping proximal and distal stumps, and running 4-0 or 5-0 absorbable sutures after completion of the bronchial anastomosis. Some measures such as systemic or local anticoagulation and a viable tissue flap to reinforce the suture line were not used in all patients.
The reconstruction mode of the bronchus is shown in Table 1. Among the types of the reconstructed bronchial tree for carcinoma, the most common one was the right upper lobectomy, which was performed on 47 patients (60.3%). Twenty-four patients (30.8%) underwent a left upper lobectomy. Other atypical types of operations were right upper and middle lobectomy, right middle lobectomy, right middle and lower lobectomy, right lower lobectomy, and left lower lobectomy. Two patients underwent a right upper sleeve lobectomy simultaneously with a resection of partial superior vena cava. Bronchoplasty was done to use sleeve lobectomy in 71 patients (91%), and a wedge resection in seven (9%). Among those cases, bronchoplasty with PA reconstruction was performed on 21 patients (26.9%) (13 PA tangential resections and eight PA sleeve resection).
|
|
|
| 3. Results |
|---|
|
|
|---|
The majority of tumors observed in the discussed series were squamous carcinomas (56 out of 75, 74.7%). Survival rates for squamous cell carcinoma were 85.5, 50.5, 41, and 35.9% for 1, 3, 5, and 10 years, respectively. No patients with adenocarcinoma survived for more than 5 years postoperatively (P=0.0875).
The 1-, 3-, 5- and 10-year survivals for patients with stage I disease were 96.7, 69.5, 66.1 and 57.5%, and for patients with stage II were 88.9, 70.4, 62.8, and 44.2%, respectively. The 1-, 3- and 5-year survivals for patients with stage III were 61.1, 11.1, and 0%, respectively. Differences observed in the survival rates were statistically significant between the patients with stages I, II and III diseases (Fig. 1 ) (P=0.0000).
|
In this series, survival rates of the 36 patients with N0 lung cancer were 87.2, 69.0, 63.3, and 52.7% at 1, 3, 5, and 10 years, respectively. For the 26 patients with N1 tumor, the values were 80.8, 61.5, 53.6, and 39.0% for 1, 3, 5, and 10 years, respectively. However, survival rates for the 13 patients with N2 tumor were 61.5 and 7.7% at 1 and 3 years, respectively, and no patients survived for more than 5 years. Based on the results, the survival rates with various pN also differed considerably (P=0.0000).
For the 21 patients who underwent bronchoplasty with PA reconstruction, 12 had left PA and nine had right PA (Table 1), and the survival was 71.4, 38.1, 33.3, and 16.7% at 1, 3, 5, and 10 years, respectively. For the 54 patients who underwent bronchoplasty but without PA reconstruction, survival rates were 90.7, 62.7, 55.0, and 47.8% at 1, 3, 5, and 10 years, respectively. Considerable differences were observed between the two groups (P=0.0033).
Of the 34 patients who did not undergo adjuvant therapy postoperatively, 25 patients were treated with chemotherapy, 14 received radiotherapy, and two had both chemotherapy and radiotherapy. No notable differences were observed in the survival rates for the three (P=0.9604).
Multivariate analysis showed that long-term results were influenced mainly by nodal stage among the five factors: pT, pN, bronchoplasty with or without PA reconstruction, cell types, and postoperative adjuvants (P=0.004).
Postoperatively, tumor recurrence around the anastomotic site confirmed by bronchoscopic biopsy was observed in four patients who underwent reconstruction of the bronchus in a period of 820 months. Of these patients, three had a wedge lobectomy and one received a sleeve lobectomy. Twelve patients were found to have local recurrence by chest CT scans. Thirty-two patients died of multiple distant metastases including eight patients with local recurrence. The data of 5-year survival rate showed that eight patients died of local recurrence (21.1%), and 27 patients died of multiple distant metastases (70.1%).
| 4. Discussion |
|---|
|
|
|---|
Patients with squamous cell carcinoma seemed to benefit from sleeve lobectomy. However, a few number of patients with adenocarcinoma and others can be used for us to conclude how histologic type can affect the survival.
Based on the reported data, it is still controversial that whether the patients with N1 and N2 diseases should undergo bronchoplasty. Some demonstrated that survival rate depends on the stage of the disease rather than the technique of the resection. Long-term survival is particularly influenced by the extent of metastasis to hilar (N1) and mediastinal nodes (N2), and most of these patients died from distant metastases [9,10]. Comparison in survival between sleeve lobectomy and pneumonectomy according to the nodal status and stage demonstrated little difference [1]. Our data showed that long-term results were influenced chiefly by the nodal stage, and the survival rates with various pN differed considerably. We found that eight of the patients with N2 diseases (8/13, 61.5%) had distant metastases, which confirmed the reported data. These data suggest that bronchoplastic procedures are also adequate for patients with N2 diseases in normal pulmonary functional reserve.
In our series, the prognosis for sleeve lobectomy with PA reconstruction (double-sleeve procedure) was not satisfactory. The result indicates that surgical reconstruction of the bronchus and PA can be an alternative to pneumonectomy when pneumonectomy is contraindicated due to low cardiopulmonary reserve.
Adjuvant therapies for non-small-cell lung cancer were found to have no significant effects on survival rates in surgical patients, and combined therapies were commonly exercised for non-surgical patients [11]. Surgery is the primary treatment for stages I and II, but the treatment for patients with stage III is somewhat in flux. The multimodal therapy including chemotherapy, radiation therapy, and surgical resection, however, is currently recommended [12]. Our data showed that there was no observed improvement in survival with the use of adjuvants, which might be influenced by the diversity in distribution of patients and therapeutic methods.
The therapeutic goal for extended operation is to do palliative resection so as to relieve symptoms and improve patients' quality of life and survival, which is most appropriate to postoperative combined therapy. A few of 5-year survivors without any recurrence of lung cancer have been reported recently [13]. In our series, two patients survived for 8 and 21 months with postoperative multimodal therapy, and died of brain and vertebral body metastases, respectively. Therefore, we believe that the indication may need to be discussed and further evaluated.
Postoperative cancer recurrence around the anastomotic site may appear, even though histologic evaluation of the resected bronchus showed no evidence of disease. In our series, we encountered four patients (5.3%) with postoperative anastomotic recurrence, which occurred in three patients by wedge lobectomy (42.9%), and was much higher than sleeve lobectomy (1.4%). To prevent postoperative local tumor recurrence around the anastomotic site, the excision of the bronchus should be wider than indicated by the histologic results of frozen sections of the bronchial stump during the operation. In addition to this procedure, it may be necessary to perform prophylactic postoperative irradiation to the anastomotic site for advanced diseases.
| 5. Conclusions |
|---|
|
|
|---|
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
F. Venuta, A. M. Ciccone, M. Anile, M. Ibrahim, T. De Giacomo, G. F. Coloni, and E. A. Rendina Reconstruction of the pulmonary artery for lung cancer: Long-term results J. Thorac. Cardiovasc. Surg., November 1, 2009; 138(5): 1185 - 1191. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Alifano, G. Cusumano, S. Strano, P. Magdeleinat, A. Bobbio, F. Giraud, B. Lebeau, and J.-F. Regnard Lobectomy with pulmonary artery resection: Morbidity, mortality, and long-term survival. J. Thorac. Cardiovasc. Surg., June 1, 2009; 137(6): 1400 - 1405. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Parissis, M. Leotsinidis, A. Hughes, E. McGovern, D. Luke, and V. Young Comparative Analysis and Outcomes of Sleeve Resection Versus Pneumonectomy Asian Cardiovasc Thorac Ann, April 1, 2009; 17(2): 175 - 182. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Ma, A. Dong, J. Fan, and H. Cheng Does sleeve lobectomy concomitant with or without pulmonary artery reconstruction (double sleeve) have favorable results for non-small cell lung cancer compared with pneumonectomy? A meta-analysis Eur. J. Cardiothorac. Surg., July 1, 2007; 32(1): 20 - 28. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Nagayasu, K. Matsumoto, T. Tagawa, A. Nakamura, N. Yamasaki, and A. Nanashima Factors affecting survival after bronchoplasty and broncho-angioplasty for lung cancer: single institutional review of 147 patients. Eur. J. Cardiothorac. Surg., April 1, 2006; 29(4): 585 - 590. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. F. Munden, S. S. Swisher, C. W. Stevens, and D. J. Stewart Imaging of the Patient with Non-Small Cell Lung Cancer Radiology, December 1, 2005; 237(3): 803 - 818. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |